Display options
Cite
Díaz Del Arco C, Ortega Medina L, Estrada Muñoz L, et al. Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis. Histol Histopathol. 2021;36(6):587-613doi: 10.14670/HH-18-309.
Díaz Del Arco, C., Ortega Medina, L., Estrada Muñoz, L., García Gómez de Las Heras, S., & Fernández Aceñero, M. J. (2021). Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis. Histology and histopathology, 36(6), 587-613. https://doi.org/10.14670/HH-18-309
Díaz Del Arco, Cristina, et al. "Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis." Histology and histopathology vol. 36,6 (2021): 587-613. doi: https://doi.org/10.14670/HH-18-309
Díaz Del Arco C, Ortega Medina L, Estrada Muñoz L, García Gómez de Las Heras S, Fernández Aceñero MJ. Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis. Histol Histopathol. 2021 Jun;36(6):587-613. doi: 10.14670/HH-18-309. Epub 2021 Feb 10. PMID: 33565601.
Copy Download .nbib Format: NLM
Share it on

Histol Histopathol. 2021 Jun;36(6):587-613. doi: 10.14670/HH-18-309. Epub 2021 Feb 10.

Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis.

Histology and histopathology

Cristina Díaz Del Arco, Luis Ortega Medina, Lourdes Estrada Muñoz, Soledad García Gómez de Las Heras, Mª Jesús Fernández Aceñero

Affiliations

  1. Department of Surgical Pathology, Hospital Clínico San Carlos, Madrid, Spain. [email protected].
  2. Complutense University of Madrid, Madrid, Spain.
  3. Department of Surgical Pathology, Hospital Clínico San Carlos, Madrid, Spain.
  4. Rey Juan Carlos University, Móstoles, Madrid, Spain.
  5. Department of Surgical Pathology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

PMID: 33565601 DOI: 10.14670/HH-18-309

Abstract

Gastric cancer (GC) is the fifth most common cancer and the third cause of cancer-related deaths worldwide. In western countries, more than half of GC patients are diagnosed at advanced stages and 5-year survival rates range between 20-30%. The only curative treatment is surgery, and despite recent advances in oncological therapies, GC prognosis is still poor. The main prognostic tool for patient categorization and treatment selection is the TNM classification, but its limitations are being increasingly recognized. Early recurrences may occur in early-stage disease, and patients at the same stage show heterogeneous outcomes. Thus, there is a need to improve GC stratification and to identify new prognostic factors, which may allow us to select drug-susceptible populations, refine patient grouping for clinical trials and discover new therapeutic targets. Molecular classifications have been developed, but they have not been translated to the clinical practice. On the other hand, histological assessment is cheap and widely available, and it is still a mainstay in the era of molecular medicine. Furthermore, histological features are acquiring new roles as reflectors of the genotype-phenotype correlation, and their potential impact on patient management is currently being analyzed. The aim of this literature review is to provide a modern overview of the histological assessment of GC. In this study, we discuss recent topics on the histological diagnosis of GC, focusing on the current role of Laurén classification and the potential value of new histological features in GC, such as inflammatory infiltration and tumor budding.

References

  1. Agnes A., Estrella J.S. and Badgwell B. (2017). The significance of a nineteenth century definition in the era of genomics: Linitis plastica. World J. Surg. Oncol. 15, 123. - PubMed
  2. Ajani J.A., Rodriguez W., Bodoky G., Moiseyenko V., Lichinitser M., Gorbunova V., Vynnychenko I., Garin A., Lang I. and Falcon S. (2010). Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial. J. Clin. Oncol. 28, 1547-1553. - PubMed
  3. Anderson W.F., Camargo M.C., Fraumeni J.F., Correa P., Rosenberg P.S. and Rabkin C.S. (2010). Age-specific trends in incidence of noncardia gastric cancer in US adults. J. Am. Med. Assoc. 303, 1723-1728. - PubMed
  4. Anderson W.F., Rabkin C.S., Turner N., Fraumeni J.F., Rosenberg P.S. and Camargo M.C. (2018). The changing face of noncardia gastric cancer incidence among US non-Hispanic whites. J. Natl. Cancer Inst. 110, 608-615. - PubMed
  5. Ang T.L. and Fock K.M. (2014). Clinical epidemiology of gastric cancer. Singapore Med. J. 55, 621-628. - PubMed
  6. Arnold M., Park J.Y., Camargo M.C., Lunet N., Forman D. and Soerjomataram I. (2020). Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. Gut 69, 823-829. - PubMed
  7. Bao B., Zheng C., Yang B., Jin Y., Hou K., Li Z., Zheng X., Yu S., Zhang X., Fan Y., Qu X., Liu Y. and Che X. (2019). Identification of subtype-specific three-gene signature for prognostic prediction in diffuse type gastric cancer. Front. Oncol. 9, 1243. - PubMed
  8. Baretton G., Kreipe H.H., Schirmacher P., Gaiser T., Hofheinz R., Berghäuser K.H., Koch W., Künzel C., Morris S. and Rüschoff J. (2019). HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany. Virchows Arch. 474, 551-560. - PubMed
  9. Becker K., Langer R., Reim D., Novotny A., Meyer Zum Buschenfelde C., Engel J., Friess H. and Hofler H. (2011). Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: A summary of 480 cases. Ann. Surg. 253, 934-939. - PubMed
  10. Ben-Shmuel A., Biber G. and Barda-Saad M. (2020). Unleashing natural killer cells in the tumor microenvironment-the next generation of immunotherapy?. Front. Immunol. 11, 275. - PubMed
  11. Berg K.B. and Schaeffer D.F. (2018). Tumor budding as a standardized parameter in gastrointestinal carcinomas: More than just the colon. Mod. Pathol. 31, 862-872. - PubMed
  12. Binato R., Santos E.C., Boroni M., Demachki S., Assumpção P. and Abdelhay E. (2018). A common molecular signature of intestinal- type gastric carcinoma indicates processes related to gastric carcinogenesis. Oncotarget 9, 7359-7371. - PubMed
  13. Biswas S.K., Allavena P. and Mantovani A. (2013). Tumor-associated macrophages: Functional diversity, clinical significance, and open questions. Semin. Immunopathol. 35, 585-600. - PubMed
  14. Blackham A.U., Swords D.S., Levine E.A., Fino N.F., Squires M.H., Poultsides G., Fields R.C., Bloomston M., Weber S.M., Pawlik T.M., Jin L.X., Spolverato G., Schmidt C., Worhunsky D., Cho C.S., Maithel S.K. and Votanopoulos K.I. (2016). Is linitis plastica a contraindication for surgical resection: A multi-institution study of the U.S. gastric cancer collaborative. Ann. Surg. Oncol. 23, 1203-1211. - PubMed
  15. Boyiadzis M.M., Kirkwood J.M., Marshall J.L., Pritchard C.C., Azad N.S. and Gulley J.L. (2018). Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J. Immunother. Cancer 6, 35. - PubMed
  16. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A. and Jemal A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 68, 394-424. - PubMed
  17. Burgain C., Germain A., Bastien C., Orry X., Choné L., Claudon M. and Laurent V. (2016). Computed tomography features of gastrointestinal linitis plastica: spectrum of findings in early and delayed phase imaging. Abdom. Radiol. 41, 1370-1377. - PubMed
  18. Caja L., Dituri F., Mancarella S., Caballero-Diaz D., Moustakas A., Giannelli G. and Fabregat I. (2018). TGF-β and the tissue microenvironment: Relevance in fibrosis and cancer. Int. J. Mol. Sci. 19, 1294. - PubMed
  19. Cancer Genome Atlas Research Network (2014). Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202-209. - PubMed
  20. Chang J.M., Lara K.A., Gray R.J., Pockaj B.A. and Wasif N. (2017). Clinical outcomes after surgery for linitis plastica of the stomach: Analysis of a population cancer registry. Am. Surg. 83, 23-29. - PubMed
  21. Charalampakis N., Economopoulou P., Kotsantis I., Tolia M., Schizas D., Liakakos T., Elimova E., Ajani J. A. and Psyrri A. (2018). Medical management of gastric cancer: a 2017 update. Cancer Med. 7, 123- 133. - PubMed
  22. Che K., Zhao Y., Qu X., Pang Z., Ni Y., Zhang T., Du J. and Shen H. (2017). Prognostic significance of tumor budding and single cell invasion in gastric adenocarcinoma. Onco Targets Ther. 10, 1039- 1047. - PubMed
  23. Chen Y.C., Fang W.L., Wang R.F., Liu C.A., Yang M.H., Lo S.S., Wu C.W., Li A.F.Y., Shyr Y.M. and Huang K.H. (2016). Clinicopathological variation of Lauren classification in gastric cancer. Pathol. Oncol. Res. 22, 197-202. - PubMed
  24. Cheng X., Yu S., Wang Y., Cui Y., Li W., Yu Y., Tang C., Jiang H., Ji Y., Sun Y., Wang X., Shen Z., Liu F. and Liu T.S. (2019). The role of oxaliplatin in the adjuvant setting of different Lauren’s type of gastric adenocarcinoma after D2 gastrectomy: a real-world study. Gastric Cancer 22, 587-597. - PubMed
  25. Cho J., Chang Y.H., Heo Y.J., Kim S., Kim N.K.D., Park J.O., Kang W.K., Lee J. and Kim K.M. (2018). Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. ESMO Open 3, e000326. - PubMed
  26. Choi Y.Y., An J.Y., Katai H., Seto Y., Fukagawa T., Okumura Y., Kim D.W., Kim H.Il, Cheong J.H., Hyung W.J. and Noh S.H. (2016). A lymph node staging system for gastric cancer: A hybrid type based on topographic and numeric systems. PLoS One 11, e0149555. - PubMed
  27. Choi J.K., Park Y.S., Jung D.H., Son S.Y., Ahn S.H., Park D.J. and Kim H. H. (2015). Clinical relevance of the tumor location-modified lauren classification system of gastric cancer. J. Gastric Cancer 15, 183- 190. - PubMed
  28. Chon H.J., Hyung W.J., Kim C., Park S., Kim J.H., Park C.H., Ahn J.B., Kim H., Chung H.C., Rha S. Y., Noh S.H. and Jeung H.C. (2017). Differential prognostic implications of gastric signet ring cell carcinoma: Stage adjusted analysis from a single high-volume center in asia. Ann. Surg. 265, 946-953. - PubMed
  29. Cisło M., Filip A.A., Offerhaus G.J.A., Ciseł B., Rawicz-Pruszyński K., Skierucha M. and Polkowski W.P. (2018). Distinct molecular subtypes of gastric cancer: From Laurén to molecular pathology. Oncotarget 9, 19427-19442. - PubMed
  30. Cortes-Ciriano I., Lee S., Park W.Y., Kim T.M. and Park P.J. (2017). A molecular portrait of microsatellite instability across multiple cancers. Nat. Commun. 8, 1-12. - PubMed
  31. Costa M.L.V., de Cássia Braga Ribeiro K., Machado M.A.C., Costa A.C.L.V. and Montagnini A.L. (2006). Prognostic score in gastric cancer: the importance of a conjoint analysis of clinical, pathologic, and therapeutic factors. Ann. Surg. Oncol. 13, 843-850. - PubMed
  32. Cristescu R., Lee J., Nebozhyn M., Kim K-M., Ting J.C., Wong S.S., Liu J., Yue Y.G., Wang J., Yu K., Ye X.S., Do I-G., Liu S., Gong L., Fu J., Jin J.G., Choi M.G., Sohn T.S., Lee J.H., Bae J.M., Kim S.T., Park S.H., Sohn I., Jung S-H., Tan P., Chen R., Hardwick J., Kang W.K., Ayers M., Hongyue D., Reinhard C., Loboda A., Kim S. and Aggarwal A. (2015). Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 21, 449-456. - PubMed
  33. Cui J., Li L., Wang C., Jin H., Yao C., Wang Y., Li D., Tian H., Niu C., Wang G., Han W., Xu J., Chen J. and Li W. (2015). Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma. Cytotherapy 17, 979- 988. - PubMed
  34. Cunningham D., Allum W.H., Stenning S.P., Thompson J.N., Van de Velde C.J.H., Nicolson M., Scarffe J.H., Lofts F.J., Falk S.J., Iveson T.J., Smith D.B., Langley R.E., Verma M., Weeden S. and Chua Y.J. (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355, 11-20. - PubMed
  35. da Silva E.Z.M., Jamur M.C. and Oliver C. (2014). Mast cell function: A new vision of an old cell. J. Histochem. Cytochem. 62, 698-738. - PubMed
  36. Dao T.V., Nguyen C.V., Nguyen Q.T., Vu H.T.N., Phung H.T., Bui O.T., Nguyen D.K., Luong B.V. and Tran T.V. (2020). Evaluation of tumor budding in predicting survival for gastric carcinoma patients in vietnam. Cancer Control 27, 1073274820968883. - PubMed
  37. Dawson H., Koelzer V.H., Karamitopoulou E., Economou M., Hammer C., Muller D.E., Lugli A. and Zlobec I. (2014). The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome. Histopathology 64, 577-584. - PubMed
  38. De Manzoni G., Verlato G., Bencivenga M., Marrelli D., Leo A.D., Giacopuzzi S., Cipollari C. and Roviello F. (2015). Impact of super- extended lymphadenectomy on relapse in advanced gastric cancer. Eur. J. Surg. Oncol. 41, 534-540. - PubMed
  39. Digklia A. and Wagner A.D. (2016). Advanced gastric cancer: Current treatment landscape and future perspectives. World J. Gastroenterol. 22, 2403-2414. - PubMed
  40. Du M., Chen L., Cheng Y., Wang Y., Fan X., Zhang Y., Zhou X., Guo L., Xu G., Zou X. and Huang Q. (2019). Tumor budding and other risk factors of lymph node metastasis in submucosal early gastric carcinoma: A multicenter clinicopathologic study in 621 radical gastrectomies of Chinese patients. Am. J. Surg. Pathol. 43, 1074- 1082. - PubMed
  41. Endo K., Sakurai M., Kusumoto E., Uehara H., Yamaguchi S., Tsutsumi N. and Ikejiri K. (2012). Biological significance of localized type IV scirrhous gastric cancer. Oncol. Lett. 3, 94-99. - PubMed
  42. Eo W.K., Jeong D.W., Chang H.J., Won K.Y., Choi S.Il, Kim S.H., Chun S.W., Oh Y.L., Lee T.H., Kim Y.O., Kim K.H., Ji Y.L., Kim A. and Kim H.Y. (2015). Absolute monocyte and lymphocyte count prognostic score for patients with gastric cancer. World J. Gastroenterol. 21, 2668-2676. - PubMed
  43. Flucke U., Mönig S.P., Baldus S.E., Zirbes T.K., Bollschweiler E., Thiele J., Dienes H.P. and Hölscher A.H. (2002). Differences between biopsy- or specimen-related Laurén and World Health Organization classification in gastric cancer. World J. Surg. 26, 137-140. - PubMed
  44. Fuchs C.S., Muro K., Tomasek J., Van Cutsem E., Cho J.Y., Oh S.C., Safran H., Bodoky G., Chau I., Shimada Y., Al-Batran S.E., Passalacqua R., Ohtsu A., Emig M., Ferry D., Chandrawansa K., Hsu Y., Sashegyi A., Liepa A.M. and Wilke H. (2017). Prognostic factor analysis of overall survival in gastric cancer from two phase iii studies of second-line ramucirumab (REGARD and RAINBOW) using pooled patient data. J. Gastric Cancer 17, 132-144. - PubMed
  45. Fuchs C.S., Doi T., Jang R.W., Muro K., Satoh T., Machado M., Sun W., Jalal S.I., Shah M.A., Metges J.P., Garrido M., Golan T., Mandala M., Wainberg Z.A., Catenacci D.V., Ohtsu A., Shitara K., Geva R., Bleeker J., Ko A.H., Ku G., Philip P., Enzinger P.C., Bang Y.J., Levitan D., Wang J., Rosales M., Dalal R.P. and Yoon H.H. (2018). Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 4, e180013. - PubMed
  46. Fujikawa H., Tanaka K., Toiyama Y., Saigusa S., Inoue Y., Uchida K. and Kusunoki M. (2012). High TrkB expression levels are associated with poor prognosis and EMT induction in colorectal cancer cells. J. Gastroenterol. 47, 775-784. - PubMed
  47. Gabbert H.E., Meier S., Gerharz C.D. and Hommel G. (1992). Tumor‐cell dissociation at the invasion front: A new prognostic parameter in gastric cancer patients. Int. J. Cancer 50, 202-207. - PubMed
  48. Giger O.T., Comtesse S.C.M., Lugli A., Zlobec I. and Kurrer M. O. (2012). Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. Mod. Pathol. 25, 1048-1053. - PubMed
  49. Goseki N., Takizawa T. and Koike M. (1992). Differences in the mode of the extension of gastric cancer classified by histological type: New histological classification of gastric carcinoma. Gut 33, 606-612. - PubMed
  50. Gronnier C., Messager M., Robb W.B., Thiebot T., Louis D., Luc G., Piessen G., Mariette C., Dhari A., Regimbeau J.M., Arnaud J.P., Brachet D., Michalak S., Collet D., Peschaud F., Dechelotte P., Flamein R., Gillet B., Mathieu B., Pezet D., Guilbert M., Leteurtre E., Poisson A., Vandois F., Glehen O., Mabrut J.Y., Pichot-Delahaye V., Delpero J.R., D’Journo X.B., Guiramand J., Thomas P.A., Glaise A., Millat B., Balon J.M., Fabre S., Borie F., Prudhomme M., Lefevre J.H., Paye F., Pocard M., Meunier B., Michot F., Tsilividis B., Brigand C., Fernandez M., Carrere N., Huten N., Kraft K., Goéré D. and Souadka A. (2013). Is the negative prognostic impact of signet ring cell histology maintained in early gastric adenocarcinoma? Surgery 154, 1093-1099. - PubMed
  51. Grundmann E. and Schlake W. (1982). Histological classification of gastric cancer from initial to advanced stages. Pathol. Res. Pract. 173, 260-274. - PubMed
  52. Gulluoglu M., Yegen G., Ozluk Y., Keskin M., Dogan S., Gundogdu G., Onder S. and Balik E. (2015). Tumor budding is independently predictive for lymph node involvement in early gastric cancer. Int. J. Surg. Pathol. 23, 349-358. - PubMed
  53. Guo Y.X., Zhang Z.Z., Zhao G. and Zhao E.H. (2019). Prognostic and pathological impact of tumor budding in gastric cancer: A systematic review and meta-analysis. World J. Gastrointest. Oncol. 11, 898- 908. - PubMed
  54. Guzinska-Ustymowicz K. (2006). MMP-9 and cathepsin B expression in tumor budding as an indicator of a more aggressive phenotype of colorectal cancer (CRC). Anticancer Res. 26, 1589-1594. - PubMed
  55. Hagerling C. and Werb Z. (2016). Neutrophils: Critical components in experimental animal models of cancer. Semin. Immunol. 28, 197- 204. - PubMed
  56. Hamada Y., Tanaka K., Hattori A. and Mizuno T. (2020). Gastric metastasis resembling linitis plastica 17 years after lobular breast cancer. Dig. Liver Dis. 52, 232. - PubMed
  57. Hamanishi J., Mandai M. and Konishi I. (2016). Immune checkpoint inhibition in ovarian cancer. Int. Immunol. 28, 339-348. - PubMed
  58. Hamashima C., Kato K., Miyashiro I., Nishida H., Takaku R., Terasawa T., Yoshikawa T., Honjo S., Inoue K., Nakayama T., Nakayama T., Narisawa R., Sagawa M., Saito H., Shibuya D. and Sobue T. (2018). Update version of the Japanese guidelines for gastric cancer screening. Jpn. J. Clin. Oncol. 48, 673-683. - PubMed
  59. Hase K., Shatney C., Johnson D., Trollope M. and Vierra M. (1993). Prognostic value of tumor ‘budding’ in patients with colorectal cancer. Dis. Colon Rectum 36, 627-635 - PubMed
  60. Henson D.E., Dittus C., Younes M., Nguyen H. and Albores-Saavedra J. (2004). Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch. Pathol. Lab. Med. 128, 765-770. - PubMed
  61. Hirotsu Y., Mochizuki H., Amemiya K., Ohyama H., Yoshimura D., Amano H., Miura Y., Ashizawa H., Nakagomi K., Takaoka S., Hosoda K., Suzuki Y., Oyama T., Hada M., Kojima Y. and Omata M. (2019). Deficiency of mismatch repair genes is less frequently observed in signet ring cell compared with non-signet ring cell gastric cancer. Med. Oncol. 36, 23. - PubMed
  62. Hu S.B., Liu C.H., Wang X., Dong Y.W., Zhao L., Liu H.F., Cao Y., Zhong D.R., Liu W., Li Y.L., Gao W.S., Bai C.M., Shang Z.H. and Li X.Y. (2019). Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer. World J. Surg. Oncol. 17, 3. - PubMed
  63. Huang K.H., Chen M.H., Fang W.L., Lin C.H., Chao Y., Lo S.S., Li A.F.Y., Wu C.W. and Shyr Y.M. (2020). The clinicopathological characteristics and genetic alterations of signet-ring cell carcinoma in gastric cancer. Cancers (Basel). 12, 1-17. - PubMed
  64. Ishigami S., Natsugoe S., Tokuda K., Nakajo A., Xiangming C., Iwashige H., Aridome K., Hokita S. and Aikou T. (2000). Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett. 159, 103-108. - PubMed
  65. Ishigami S., Natsugoe S., Tokuda K., Nakajo A., Okumura H., Matsumoto M., Miyazono F., Hokita S. and Aikou T. (2003). Tumor-associated macrophage (TAM) infiltration in gastric cancer. Anticancer Res. 23, 4079-4083. - PubMed
  66. Jafferbhoy S., Shiwani H. and Rustum Q. (2013). Managing gastric linitis plastica: Keep the scalpel sheathed. Sultan Qaboos Univ. Med. J. 13, 451-453. - PubMed
  67. Jiménez Fonseca P., Carmona-Bayonas A., Hernández R., Custodio A., Cano J.M., Lacalle A., Echavarria I., Macias I., Mangas M., Visa L., Buxo E., Álvarez Manceñido F., Viudez A., Pericay C., Azkarate A., Ramchandani A., López C., Martinez De Castro E., Fernández Montes A., Longo F., Sánchez Bayona R., Limón M.L., Diaz-Serrano A., Martin Carnicero A., Arias D., Cerdà P., Rivera F., Vieitez J.M., Sánchez Cánovas M., Garrido M. and Gallego J. (2017). Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: Real-world data from the AGAMENON National Cancer Registry. Br. J. Cancer 117, 775-782. - PubMed
  68. Jin S., Xu B., Yu L., Fu Y., Wu H., Fan X., Wei J. and Liu B. (2017). The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy. Oncotarget 8, 38850-38862. - PubMed
  69. Jung K., Park M.I., Kim S.E. and Park S.J. (2016). Borrmann type 4 advanced gastric cancer: Focus on the development of scirrhous gastric cancer. Clin. Endosc. 49, 336-345. - PubMed
  70. Kang S.H., Kim J.S., Moon H.S., Lee E.S., Kim S.H., Sung J.K., Lee B.S. and Jeong H. Y. (2017). Signet ring cell carcinoma of early gastric cancer, is endoscopic treatment really risky? Med. (United States) 96, e7532. - PubMed
  71. Kao Y.C., Fang W.L., Wang R.F., Li A.F.Y., Yang M.H., Wu C.W., Shyr Y.M. and Huang K.H. (2019). Clinicopathological differences in signet ring cell adenocarcinoma between early and advanced gastric cancer. Gastric Cancer 22, 255-263. - PubMed
  72. Von Karsa L., Patnick J., Segnan N., Atkin W., Halloran S., LansdorpVogelaar I., Malila N., Minozzi S., Moss S., Quirke P., Steele R.J., Vieth M., Aabakken L., Altenhofen L., Ancelle-Park R., Antoljak N., Anttila A., Armaroli P., Arrossi S., Austoker J., Banzi R., Bellisario C., Blom J., Brenner H., Bretthauer M., Cancela M.C., Costamagna G., Cuzick J., Dai M., Daniel J., Dekker E., Delicata N., Ducarroz S., Erfkamp H., Espinàs J. A., Faivre J., Wood L. F., Flugelman A., Frkovic-Grazio S., Geller B., Giordano L., Grazzini G., Green J., Hamashima C., Herrmann C., Hewitson P., Hoff G., Holten I., Jover R., Kaminski M.F., Kuipers E.J., Kurtinaitis J., Lambert R., Launoy G., Lee W., Leicester R., Leja M., Lieberman D., Lignini T., Lucas E., Lynge E., Mádai S., Marinho J., Zakotnik J.M., Minoli G., Monk C., Morais A., Muwonge R., Nadel M., Neamtiu L., Tuser M.P., Pignone M., Pox C., Primic-Zakelj M., Psaila J., Rabeneck L., Ransohoff D., Rasmussen M., Regula J., Ren J., Rennert G., Rey J., Riddell R.H., Risio M., Rodrigues V., Saito H., Sauvaget C., Scharpantgen A., Schmiegel W., Senore C., Siddiqi M., Sighoko D., Smith R., Smith S., Suchanek S., Suonio E., Tong W., Törnberg S., Van Cutsem E., Vignatelli L., Villain P., Voti L., Watanabe H., Watson J., Winawer S., Young G., Zaksas V., Zappa M. and Valori R. (2013). European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication. Endoscopy 45, 51-59. - PubMed
  73. Kato K., Chin K., Yoshikawa T., Yamaguchi K., Tsuji Y., Esaki T., Sakai K., Kimura M., Hamaguchi T., Shimada Y., Matsumura Y. and Ikeda R. (2012). Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest. New Drugs 30, 1621-1627. - PubMed
  74. Kemi N., Eskuri M., Ikäläinen J., Karttunen T.J. and Kauppila J.H. (2019). Tumor budding and prognosis in gastric adenocarcinoma. Am. J. Surg. Pathol. 43, 229-234. - PubMed
  75. Kim K.J., Wen X.Y., Yang H.K., Kim W.H. and Kang G. H. (2015). Prognostic implication of M2 macrophages are determined by the proportional balance of tumor associated macrophages and tumor infiltrating lymphocytes in microsatellite-unstable gastric carcinoma. PLoS One 10, e0144192. - PubMed
  76. Kim H., Kwon H.J., Park S.Y., Park E. and Chung J.H. (2017). PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: A comparative study. Oncotarget 8, 98524-98532. - PubMed
  77. Kim T.S., Da Silva E., Coit D.G. and Tang L.H. (2019). Intratumoral immune response to gastric cancer varies by molecular and histologic subtype. Am. J. Surg. Pathol. 43, 851-860. - PubMed
  78. Kim J.S., Kang S.H., Moon H.S., Lee E.S., Kim S.H., Sung J.K., Lee B.S. and Jeong H.Y. (2020). Accuracy of endoscopic size measurements of early gastric signet ring cell carcinoma. Surg. Endosc. (in press). - PubMed
  79. Kinoshita H., Yashiro M., Fukuoka T., Hasegawa T., Morisaki T., Kasashima H., Masuda G., Noda S. and Hirakawa K. (2015). Diffuse-type gastric cancer cells switch their driver pathways from FGFR2 signaling to SDF1/CXCR4 axis in hypoxic tumor microenvironments. Carcinogenesis 36, 1511-1520. - PubMed
  80. Kitadai Y. (2010). Angiogenesis and lymphangiogenesis of gastric cancer. J. Oncol. 2010, 468725 - PubMed
  81. Koelzer V.H., Karamitopoulou E., Dawson H., Kondi-Pafiti A., Zlobec I. and Lugli A. (2013). Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer. Br. J. Cancer 108, 2088- 2096. - PubMed
  82. Koelzer V.H., Langer R., Zlobec I. and Lugli A. (2014). Tumor budding in upper gastrointestinal carcinomas. Front. Oncol. 4, 216. - PubMed
  83. Kozuki T., Yao T., Nakamura S., Matsumoto T. and Tsuneyoshi M. (2002). Differences in p53 and cadherin-catenin complex expression between histological subtypes in diffusely infiltrating gastric carcinoma. Histopathology 41, 56-64. - PubMed
  84. Kupferman M.E., Jiffar T., El-Naggar A., Yilmaz T., Zhou G., Xie T., Feng L., Wang J., Holsinger F. C., Yu D. and Myers J. N. (2010). TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene 29, 2047-2059. - PubMed
  85. Kwee R.M. and Kwee T.C. (2007). Imaging in local staging of gastric cancer: A systematic review. J. Clin. Oncol. 25, 2107-2116. - PubMed
  86. Lamouille S., Xu J. and Derynck R. (2014). Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178- 196. - PubMed
  87. Laurén P. (1965). The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 64, 31-49. - PubMed
  88. Le D.T., Uram J.N., Wang H., Bartlett B.R., Kemberling H., Eyring A.D., Skora A.D., Luber B.S., Azad N.S., Laheru D., Biedrzycki B., Donehower R.C., Zaheer A., Fisher G.A., Crocenzi T.S., Lee J.J., Duffy S.M., Goldberg R.M., de la Chapelle A., Koshiji M., Bhaijee F., Huebner T., Hruban R.H., Wood L.D., Cuka N., Pardoll D.M., Papadopoulos N., Kinzler K.W., Zhou S., Cornish T.C., Taube J.M., Anders R.A., Eshleman J.R., Vogelstein B. and Diaz L. A. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520. - PubMed
  89. Lee J., Lim T., Uhm J. E., Park K.W., Park S.H., Lee S.C., Park J.O., Park Y.S., Lim H.Y., Sohn T.S., Noh J.H., Heo J.S., Park C.K., Kim S. and Kang W. K. (2007). Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann. Oncol. 18, 886-891. - PubMed
  90. Lee S.H., Choi C.W., Kim S.J., Choi C.I., Kim D.H., Jeon T.Y., Kim D.H., Lee H.J., Kim K.H. and Hwang S.H. (2016). Risk factors for lymph node metastasis in mucosal gastric cancer and re-evaluation of endoscopic submucosal dissection. Ann. Surg. Treat. Res. 91, 118- 126. - PubMed
  91. Lee J.Y., Gong E.J., Chung E.J., Park H.W., Bae S.E., Kim E.H., Kim J., Do Y.S., Kim T.H., Chang H.S., Song H.J., Choe J. and Jung H.Y. (2017a). The characteristics and prognosis of diffuse-type early gastric cancer diagnosed during health check-ups. Gut Liver 11, 807-812. - PubMed
  92. Lee D., Ham I.H., Son S.Y., Han S.U., Kim Y.B. and Hur H. (2017b). Intratumor stromal proportion predicts aggressive phenotype of gastric signet ring cell carcinomas. Gastric Cancer 20, 591-601. - PubMed
  93. Lee J.H., Chang K.K., Yoon C., Tang L.H., Strong V.E. and Yoon S.S. (2018a). Lauren histologic type is the most important factor associated with pattern of recurrence following resection of gastric adenocarcinoma. Ann. Surg. 267, 105-113. - PubMed
  94. Lee D., Son S.Y., Kim Y.B., Han S.U. and Hur H. (2018b). Neural invasion is a significant contributor to peritoneal recurrence in signet ring cell gastric carcinoma. Ann. Surg. Oncol. 25, 1167-1175. - PubMed
  95. Lee J.S., Won H.S., Sun D.S., Hong J.H. and Ko Y.H. (2018c). Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: A systematic review and meta-analysis. Medicine (Baltimore) 97, e11769. - PubMed
  96. Li X., Zhu X., Wang Y., Wang R., Wang L., Zhu M. L. and Zheng L. (2019). Prognostic value and association of Lauren classification with VEGF and VEGFR-2 expression in gastric cancer. Oncol. Lett. 18, 4891-4899. - PubMed
  97. Li R., Zhang H., Cao Y., Liu X., Chen Y., Qi Y., Wang J., Yu K., Lin C., Liu H., He H., Li H., Chen L., Shen Z., Qin J., Zhang W., Sun Y. and Xu J. (2020). Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8+ T cells in gastric cancer. Cancer Immunol. Immunother. 69, 1327-1336. - PubMed
  98. Lordick F., Kang Y.K., Chung H.C., Salman P., Oh S.C., Bodoky G., Kurteva G. Volovat C., Moiseyenko V.M., Gorbunova V., Park J.O., Sawaki A., Celik I., Gotte H., Melezinkova H. and Moehler M. (2013). Capecitabine and cisplatin with or without cetuximab for patientst with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 14, 490-499. - PubMed
  99. Luu C., Thapa R., Woo K., Coppola D., Almhanna K., Pimiento J. M., Chen D.T., Marquez D.D. and Hodul P.J. (2017). Does histology really influence gastric cancer prognosis? J. Gastrointest. Oncol. 8, 1026-1036. - PubMed
  100. Lv Y., Zhao Y., Wang X., Chen N., Mao F., Teng Y., Wang T., Peng L., Zhang J., Cheng P., Liu Y., Kong H., Chen W., Hao C., Han B., Ma Q., Zou Q., Chen J. and Zhuang Y. (2019). Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway. J. Immunother. Cancer 7, 54. - PubMed
  101. Ma C., Patel K., Singhi A.D., Ren B., Zhu B., Shaikh F. and Sun W. (2016a). Programmed death-ligand 1 expression is common in gastric cancer associated with Epstein-Barr virus or microsatellite instability. Am. J. Surg. Pathol. 40, 1496-1506. - PubMed
  102. Ma J., Shen H., Kapesa L. and Zeng S. (2016b). Lauren classification and individualized chemotherapyin gastric cancer (Review). Oncol. Lett. 11, 2959-2964. - PubMed
  103. Maoz A., Dennis M. and Greenson J.K. (2019). The Crohn’s-like lymphoid reaction to colorectal cancer-tertiary lymphoid structures with immunologic and potentially therapeutic relevance in colorectal cancer. Front. Immunol. 10, 1884. - PubMed
  104. Marrelli D., Polom K., Neri A. and Roviello F. (2018). Clinical impact of molecular classifications in gastric cancer. Updates Surg. 70, 225- 232. - PubMed
  105. Mastoraki A., Papanikolaou I.S., Sakorafas G. and Safioleas M. (2009). Facing the challenge of managing linitis plastica--review of the literature. Hepatogastroenterology 56, 1773-1778. - PubMed
  106. Masucci M.T., Minopoli M. and Carriero M. V. (2019). Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy. Front. Oncol. 9, 1146 - PubMed
  107. Max N., Harbaum L., Pollheimer M.J., Lindtner R.A., Kornprat P. and Langner C. (2016). Tumour budding with and without admixed inflammation: Two different sides of the same coin? Br. J. Cancer 114, 368-371. - PubMed
  108. Mengardo V., Treppiedi E., Bencivenga M., Dal Cero M. and Giacopuzzi S. (2018). Tailored treatment for signet ring cell gastric cancer. Updates Surg. 70, 167-171. - PubMed
  109. Min L., Zhao Y., Zhu S., Qiu X., Cheng R., Xing J., Shao L., Guo S. and Zhang S. (2017). Integrated analysis identifies molecular signatures and specific prognostic factors for different gastric cancer subtypes. Transl. Oncol. 10, 99-107. - PubMed
  110. Ming S‐C. (1977). Gastric carcinoma: A pathobiological classification. Cancer 39, 2475-2485. - PubMed
  111. Mizuno R., Kawada K., Itatani Y., Ogawa R., Kiyasu Y. and Sakai Y. (2019). The role of tumor-associated neutrophils in colorectal cancer. Int. J. Mol. Sci. 20, 529. - PubMed
  112. Morgant S., Artru P., Oudjit A., Lourenco N., Pasquer A., Walter T., Gornet J.M., Rouquette A., Lledo G., Brezault C. and Coriat R. (2018). Computed tomography scan efficacy in staging gastric linitis plastica lesion: A retrospective multicentric french study. Cancer Manag. Res. 10, 3825-3831. - PubMed
  113. Mukai K., Tsai M., Saito H. and Galli S.J. (2018). Mast cells as sources of cytokines, chemokines, and growth factors. Immunol. Rev. 282, 121-150. - PubMed
  114. Murphy G., Pfeiffer R., Camargo M.C. and Rabkin C. S. (2009). Metaanalysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 137, 824-833. - PubMed
  115. Narahara H., Iishi H., Imamura H., Tsuburaya A., Chin K., Imamoto H., Esaki T., Furukawa H., Hamada C. and Sakata Y. (2011). Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 14, 72-80. - PubMed
  116. Nie R.C., Yuan S.Q., Li Y.F., Chen Y.M., Chen X.J., Zhu B.Y., Xu L.P., Zhou Z.W., Chen S. and Chen Y.B. (2017). Clinicopathological characteristics and prognostic value of signet ring cells in gastric carcinoma: A meta-analysis. J. Cancer 8, 3396-3404. - PubMed
  117. Olsen S., Jin L., Fields R.C., Yan Y. and Nalbantoglu IlI. (2017). Tumor budding in intestinal-type gastric adenocarcinoma is associated with nodal metastasis and recurrence. Hum. Pathol. 68, 26-33. - PubMed
  118. Omura Y., Toiyama Y., Okugawa Y., Yamamoto A., Yin C., Kusunoki K., Kusunoki Y., Shigemori T., Ide S., Kitajima T., Fujikawa H., Yasuda H., Hiro J., Yoshiyama S., Ohi M. and Kusunoki M. (2020). Crohn’slike lymphoid reaction is associated with oncological prognosis and nutritional status in patients with pathological stage II/III gastric cancer. Ann. Surg. Oncol. 27, 259-267 - PubMed
  119. Oue N., Sentani K., Sakamoto N., Uraoka N. and Yasui W. (2019). Molecular carcinogenesis of gastric cancer: Lauren classification, mucin phenotype expression, and cancer stem cells. Int. J. Clin. Oncol. 24, 771-778. - PubMed
  120. Palli D., Bianchi S., Cipriani F., Duca P., Amorosi A., Avellini C., Russo A., Saragoni A., Todde P., Valdes E., Vindigni C., Blot W.J., Fraumeni J.F. and Buiatti E. (1991). Reproducibility of histologie classification of gastric cancer. Br. J. Cancer 63, 765-768. - PubMed
  121. Park S.Y., Kook M.C., Kim Y.W., Cho N.Y., Kim T.Y. and Kang G.H. (2010). Mixed-type gastric cancer and its association with highfrequency CpG island hypermethylation. Virchows Arch. 456, 625- 633. - PubMed
  122. Park S.H., Sohn T.S., Lee J., Lim D.H., Hong M.E., Kim K.M., Sohn I., Jung S.H., Choi M.G., Lee J.H., Bae J.M., Kim S., Kim S.T., Park J.O., Park Y.S., Lim H.Y. and Kang W.K. (2015). Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: Final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J. Clin. Oncol. 33, 3130-3136. - PubMed
  123. Park H.K., Lee K.Y., Yoo M.W., Hwang T.S. and Han H.S. (2016). Mixed carcinoma as an independent prognostic factor in submucosal invasive gastric carcinoma. J. Korean Med. Sci. 31, 866-872. - PubMed
  124. Pedrazzani C., Marrelli D., Pacelli F., Di Cosmo M., Mura G., Bettarini F., Rosa F., De Manzoni G. and Roviello F. (2012). Gastric linitis plastica: Which role for surgical resection? Gastric Cancer 15, 56- 60. - PubMed
  125. Persiani R., D’Ugo D., Rausei S., Sermoneta D., Barone C., Pozzo C., Ricci R., La Torre G. and Picciocchi A. (2005). Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy. J. Surg. Oncol. 89, 227-236. - PubMed
  126. Petrelli F., Berenato R., Turati L., Mennitto A., Steccanella F., Caporale M., Dallera P., de Braud F., Pezzica E., Di Bartolomeo M., Sgroi G., Mazzaferro V., Pietrantonio F. and Barni S. (2017). Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: A systematic review and meta-analysis. J. Gastrointest. Oncol. 8, 148-163. - PubMed
  127. Petryszyn P., Chapelle N. and Matysiak-Budnik T. (2020). Gastric cancer: Where are we heading?. Dig. Dis. 38, 280-285. - PubMed
  128. Piessen G., Messager M., Leteurtre E., Jean-Pierre T. and Mariette C. (2009). Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann. Surg. 250, 878-887. - PubMed
  129. Polom K., Marano L., Marrelli D., De Luca R., Roviello G., Savelli V., Tan P. and Roviello F. (2018). Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br. J. Surg. 105, 159-167. - PubMed
  130. Postlewait L.M., Squires M.H., Kooby D.A., Poultsides G.A., Weber S.M., Bloomston M., Fields R.C., Pawlik T.M., Votanopoulos K.I., Schmidt C.R., Ejaz A., Acher A.W., Worhunsky D.J., Saunders N., Swords D., Jin L.X., Cho C.S., Winslow E.R., Cardona K., Staley C.A. and Maithel S.K. (2015). The prognostic value of signet-ring cell histology in resected gastric adenocarcinoma. Ann. Surg. Oncol. 22, 832-839. - PubMed
  131. Powell D.R. and Huttenlocher A. (2016). Neutrophils in the tumor microenvironment. Trends Immunol. 37, 41-52. - PubMed
  132. Puppa G., Senore C., Sheahan K., Vieth M., Lugli A., Zlobec I., Pecori S., Wang L.M., Langner C., Mitomi H., Nakamura T., Watanabe M., Ueno H., Chasle J., Conley S.A., Herlin P., Lauwers G.Y. and Risio M. (2012). Diagnostic reproducibility of tumour budding in colorectal cancer: A multicentre, multinational study using virtual microscopy. Histopathology 61, 562-575. - PubMed
  133. Pyke C., Salo S., Ralfkiaer E., Romer J., Dano K. and Tryggvason K. (1995). Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res. 55, 4132-4139. - PubMed
  134. Pyo J.H., Ahn S., Lee H., Min B.H., Lee J.H., Shim S.G., Choi M.G., Lee J.H., Sohn T.S., Bae J.M., Kim K.M., Yeon S., Jung S.H., Kim J.J. and Kim S. (2016). Clinicopathological features and prognosis of mixed-type T1a gastric cancer based on Lauren’s classification. Ann. Surg. Oncol. 23, 784-791. - PubMed
  135. Qi B., Liu L., Pan Y., Xu S. and Li J. (2020). Prognostic significance of peritumoural and intratumoural budding in intestinal-type gastric adenocarcinoma. Arab J. Gastroenterol. 21, 111-116. - PubMed
  136. Rawicz-Pruszyński K., Mielko J., Pudło K., Lisiecki R., Skoczylas T., Murawa D. and Polkowski W. P. (2019). Yield of staging laparoscopy in gastric cancer is influenced by Laurén histologic subtype. J. Surg. Oncol. 120, 1148-1153. - PubMed
  137. Rawla P. and Barsouk A. (2019). Epidemiology of gastric cancer: Global trends, risk factors and prevention. Prz. Gastroenterol. 14, 26-38. - PubMed
  138. Ren J., Niu G., Wang X., Song T., Hu Z. and Ke C. (2018). Effect of age on prognosis of gastric signet-ring cell carcinoma: A SEER database analysis. Med. Sci. Monit. 24, 8524-8532. - PubMed
  139. Rodriquenz M.G., Roviello G., D’Angelo A., Lavacchi D., Roviello F. and Polom K. (2020). MSI and EBV positive gastric cancer’s subgroups and their link with novel immunotherapy. J. Clin. Med. 9, 1427. - PubMed
  140. Ronellenfitsch U., Lippert C., Grobholz R., Lang S., Post S., Kähler G. and Gaiser T. (2016). Histology-based prediction of lymph node metastases in early gastric cancer as decision guidance for endoscopic resection. Oncotarget 7, 10676-10683. - PubMed
  141. de Rosa S., Sahnane N., Tibiletti M.G., Magnoli F., Vanoli A., Sessa F. and Chiaravalli A.M. (2018). EBV+ and MSI gastric cancers harbor high PD-L1/PD-1 expression and high CD8+ intratumoral lymphocytes. Cancers (Basel). 10, 102. - PubMed
  142. Roy P., Piard F., Dusserre-Guion L., Martin L., Michiels-Marzais D. and Faivre J. (1998). Prognostic comparison of the pathological classifications of gastric cancer: A population-based study. Histopathology 33, 304-310. - PubMed
  143. Saito A., Shimoda T., Nakanishi Y., Ochiai A. and Toda G. (2001). Histologic heterogeneity and mucin phenotypic expression in early gastric cancer. Pathol. Int. 51, 165-171. - PubMed
  144. Saito H., Takaya S., Osaki T. and Ikeguchi M. (2013). Increased apoptosis and elevated Fas expression in circulating natural killer cells in gastric cancer patients. Gastric Cancer 16, 473-479. - PubMed
  145. Salgado R., Denkert C., Demaria S., Sirtaine N., Klauschen F., Pruneri G., Wienert S., Van den Eynden G., Baehner F.L., Penault-Llorca F., Perez E.A., Thompson E.A., Symmans W.F., Richardson A.L., Brock J., Criscitiello C., Bailey H., Ignatiadis M., Floris G., Sparano J., Kos Z., Nielsen T., Rimm D.L., Allison K.H., Reis-Filho J.S., Loibl S., Sotiriou C., Viale G., Badve S., Adams S., Willard-Gallo K. and Loi S. (2015). The evaluation of tumor-infiltrating lymphocytes (TILS) in breast cancer: Recommendations by an International TILS Working Group 2014. Ann. Oncol. 26, 259-271. - PubMed
  146. Sammarco G., Varricchi G., Ferraro V., Ammendola M., De Fazio M., Altomare D.F., Luposella M., Maltese L., Currò G., Marone G., Ranieri G. and Memeo R. (2019). Mast cells, angiogenesis and lymphangiogenesis in human gastric cancer. Int. J. Mol. Sci. 20, 2106. - PubMed
  147. Sano T. and Kodera Y. (2011). Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14, 101-112. - PubMed
  148. Sato Y., Wada I., Odaira K., Hosoi A., Kobayashi Y., Nagaoka K., Karasaki T., Matsushita H., Yagi K., Yamashita H., Fujita M., Watanabe S., Kamatani T., Miya F., Mineno J., Nakagawa H., Tsunoda T., Takahashi S., Seto Y. and Kakimi K. (2020). Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumorinfiltrating cells. Clin. Transl. Immunol. 9, e1194. - PubMed
  149. Shah M.A., Khanin R., Tang L., Janjigian Y.Y., Klimstra D.S., Gerdes H. and Kelsen D.P. (2011). Molecular classification of gastric cancer: A new paradigm. Clin. Cancer Res. 17, 2693-2701. - PubMed
  150. Shan G.D., Xu G.Q. and Li Y.M. (2013). Endoscopic ultrasonographic features of gastric linitis plastica in fifty-five Chinese patients. J. Zhejiang Univ. Sci. B 14, 844-848. - PubMed
  151. Shi T., Song X., Liu Q., Yang Y., Yu L., Liu B. and Wei J. (2019). Survival benefit of palliative gastrectomy followed by chemotherapy in stage IV gastric signet ring cell carcinoma patients: A large population-based study. Cancer Med. 8, 6010-6020. - PubMed
  152. Smyth E.C., Verheij M., Allum W., Cunningham D., Cervantes A., Arnold D. and on behalf of the ESMO Guidelines Committee (2016). Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27, v38-v49. - PubMed
  153. Studer L., Blank A., Bokhorst J., Nagtegaal I. D., Zlobec I., Lugli A., Fischer A. and Dawson H. (2021). Taking tumour budding to the next frontier - a post‐ITBCC 2016 review. Histopathology. 78, 476- 484 - PubMed
  154. Taghavi S., Jayarajan S.N., Davey A. and Willis A. I. (2012). Prognostic significance of signet ring gastric cancer. J. Clin. Oncol. 30, 3493- 3498. - PubMed
  155. Tanaka K., Shimura T., Kitajima T., Kondo S., Ide S., Okugawa Y., Saigusa S., Toiyama Y., Inoue Y., Araki T., Uchida K., Mohri Y. and Kusunoki M. (2014). Tropomyosin-related receptor kinase B at the invasive front and tumour cell dedifferentiation in gastric cancer. Br. J. Cancer 110, 2923-2934. - PubMed
  156. Tang C-T., Zeng L., Yang J., Zeng C. and Chen Y. (2020). Analysis of the incidence and survival of gastric cancer based on the lauren classification: A large population-based study using SEER. Front. Oncol. 10, 1212. - PubMed
  157. Terai S., Fushida S., Tsukada T., Kinoshita J., Oyama K., Okamoto K., Makino I., Tajima H., Ninomiya I., Fujimura T., Harada S. and Ohta T. (2015). Bone marrow derived “fibrocytes” contribute to tumor proliferation and fibrosis in gastric cancer. Gastric Cancer 18, 306- 313. - PubMed
  158. Thompson R., Ranaghan L., Kennedy R., Clements W.D.B., Carey P.D. and Kennedy J. A. (2017). Survival following operative management of gastric linitis plastica compared with non-operative management. Ann. R. Coll. Surg. Engl. 99, 228-232. - PubMed
  159. Thompson E.D., Zahurak M., Murphy A., Cornish T., Cuka N., Abdelfatah E., Yang S., Duncan M., Ahuja N., Taube J.M., Anders R.A. and Kelly R. J. (2016). Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 66, 794-801. - PubMed
  160. Toiyama Y., Yasuda H., Saigusa S., Matushita K., Fujikawa H., Tanaka K., Mohri Y., Inoue Y., Goel A. and Kusunoki M. (2012). Coexpression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c Met signaling in gastric cancer. Int. J. Cancer 130, 2912-2921. - PubMed
  161. Ueno H., Murphy J., Jass J.R., Mochizuki H. and Talbot I.C. (2002). Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 40, 127-132. - PubMed
  162. Ulase D., Heckl S., Behrens H.M., Krüger S. and Röcken C. (2020). Prognostic significance of tumour budding assessed in gastric carcinoma according to the criteria of the International Tumour Budding Consensus Conference. Histopathology 76, 433-446. - PubMed
  163. Van Beek J., Zur Hausen A., Snel S.N., Berkhof J., Kranenbarg E.K., Van De Velde C.J.H., Van Den Brule A.J.C., Middeldorp J.M., Meijer C.J.L.M. and Bloemena E. (2006). Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases. Am. J. Surg. Pathol. 30, 59-65. - PubMed
  164. Varricchi G., Galdiero M.R., Loffredo S., Marone G., Iannone R., Marone G. and Granata F. (2017). Are mast cells MASTers in cancer?. Front. Immunol. 8, 424 - PubMed
  165. Vivier-Chicoteau J., Lambert J., Coriat R., Bonnot P.E., Goere D., Roche B., Dior M., Goujon G., Morgant S., Pocard M., Glehen O., Aparicio T. and Gornet J. M. (2020). Development and internal validation of a diagnostic score for gastric linitis plastica. Gastric Cancer 23, 639-647. - PubMed
  166. Voron T., Messager M., Duhamel A., Lefevre J., Mabrut J.Y., Goere D., Meunier B., Brigand C., Hamy A., Glehen O., Mariette C. and Paye F. (2016). Is signet-ring cell carcinoma a specific entity among gastric cancers? Gastric Cancer 19, 1027-1040. - PubMed
  167. Wang B., Xu D., Yu X., Ding T., Rao H., Zhan Y., Zheng L. and Li L. (2011). Association of intra-tumoral infiltrating macrophages and regulatory T cells is an independent prognostic factor in gastric cancer after radical resection. Ann. Surg. Oncol. 18, 2585-2593. - PubMed
  168. Wang Z., Xu J., Shi Z., Shen X., Luo T., Bi J. and Nie M. (2016a). Clinicopathologic characteristics and prognostic of gastric cancer in young patients. Scand. J. Gastroenterol. 51, 1043-1049. - PubMed
  169. Wang X., Zhao L., Liu H., Zhong D., Liu W., Shan G., Dong F., Gao W., Bai C. and Li X. (2016b). A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer. Br. J. Cancer 114, 1326-1333. - PubMed
  170. Wang H., Xing X.M., Ma L.N., Liu L., Hao J., Feng L.X. and Yu Z. (2018). Metastatic lymph node ratio and lauren classification are independent prognostic markers for survival rates of patients with gastric cancer. Oncol. Lett. 15, 8853-8862. - PubMed
  171. Wang K., Li E., Busuttil R.A., Kong J.C., Pattison S., Sung J.J. Y., Yu J., El-Omar E.M., Simpson J.A. and Boussioutas A. (2020a). A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer. Ther. Adv. Med. Oncol. 12, 1758835920930359. - PubMed
  172. Wang Y., Zhai J., Zhang T., Han S., Zhang Y., Yao X. and Shen L. (2020b). Tumor-associated neutrophils can predict lymph node metastasis in early gastric cancer. Front. Oncol. 10, 570113. - PubMed
  173. Watanabe T., Itabashi M., Shimada Y., Tanaka S., Ito Y., Ajioka Y., Hamaguchi T., Hyodo I., Igarashi M., Ishida H., Ishiguro M., Kanemitsu Y., Kokudo N., Muro K., Ochiai A., Oguchi M., Ohkura Y., Saito Y., Sakai Y., Ueno H., Yoshino T., Fujimori T., Koinuma N., Morita T., Nishimura G., Sakata Y., Takahashi K., Takiuchi H., Tsuruta O., Yamaguchi T., Yoshida M., Yamaguchi N., Kotake K. and Sugihara K. (2012). Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int. J. Clin. Oncol. 17, 1-29. - PubMed
  174. Wei F., Lyu H., Wang S., Chu Y. and Chen F. (2019). Postoperative radiotherapy improves survival in gastric signet-ring cell carcinoma: A seer database analysis. J. Gastric Cancer 19, 393-407. - PubMed
  175. Wittekind C. (2015). The development of the TNM classification of gastric cancer. Pathol. Int. 65, 399-403. - PubMed
  176. Woo S.R., Corrales L. and Gajewski T.F. (2015). The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 36, 250-256. - PubMed
  177. Woo C.G., Ho W.J., Park Y.S., Park S.R., Ryu M.H., Jung H.Y. and Kang Y. K. (2017). A potential pitfall in evaluating HER2 immunohistochemistry for gastric signet ring cell carcinomas. Pathology 49, 38-43. - PubMed
  178. Wu H., Xu J.B., He Y.L., Peng J.J., Zhang X.H., Chen C.Q., Li W. and Cai S.R. (2012). Tumor-associated macrophages promote angiogenesis and lymphangiogenesis of gastric cancer. J. Surg. Oncol. 106, 462-468. - PubMed
  179. Xiao Y. and Freeman G.J. (2015). The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov. 5, 16-18. - PubMed
  180. Yamada N., Sugai T., Eizuka M., Tsuchida K., Sugimoto R., Mue Y., Suzuki M., Osakabe M., Uesugi N., Ishida K., Otsuka K. and Matsumoto T. (2017). Tumor budding at the invasive front of colorectal cancer may not be associated with the epithelialmesenchymal transition. Hum. Pathol. 60, 151-159. - PubMed
  181. Yamaguchi K., Tada M., Horikoshi N., Otani T., Takiuchi H., Saitoh S., Kanamaru R., Kasai Y., Koizumi W., Sakata Y. and Taguchi T. (2002). Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 5, 90-95. - PubMed
  182. Yashiro M. and Hirakawa K. (2010). Cancer-stromal interactions in scirrhous gastric carcinoma. Cancer Microenviron. 3, 127- 135. - PubMed
  183. Ychou M., Boige V., Pignon J.P., Conroy T., Bouché O., Lebreton G., Ducourtieux M., Bedenne L., Fabre J.M., Saint-Aubert B., Genève J., Lasser P. and Rougier P. (2011). Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. J. Clin. Oncol. 29, 1715-1721. - PubMed
  184. Yin S., Huang J., Li Z., Zhang J., Luo J., Lu C., Xu H. and Xu H. (2017). The prognostic and clinicopathological significance of tumorassociated macrophages in patients with gastric cancer: A metaanalysis. PLoS One 12, e170042. - PubMed
  185. Yonemura Y., Canbay E., Li Y., Coccolini F., Glehen O., Sugarbaker P.H., Morris D., Moran B., Gonzaletz-Moreno S., Deraco M., Piso P., Elias D., Batlett D., Ishibashi H., Mizumoto A., Verwaal V. and Mahtem H. (2016). A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur. J. Surg. Oncol. 42, 1123-1131. - PubMed
  186. Yoon H.J., Kim Y.H., Kim J.H., Kim H.K., Kim H., Park J.J., Youn Y.H., Park H., Kim J.W., Hyung W.J., Noh S.H. and Choi S.H. (2016). Are new criteria for mixed histology necessary for endoscopic resection in early gastric cancer? Pathol. Res. Pract. 212, 410-414. - PubMed
  187. Yu P.C., Long D., Liao C.C. and Zhang S. (2018). Association between density of tumor-infiltrating lymphocytes and prognoses of patients with gastric cancer. Medicine (Baltimore) 97, e11387. - PubMed
  188. Zaanan A. and Taieb J. (2019). How to better select patients with advanced gastric cancer for immunotherapy. Transl. Gastroenterol. Hepatol. 4, 6. - PubMed
  189. Zhang H., Wang X., Shen Z., Xu J., Qin J. and Sun Y. (2015). Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection. Gastric Cancer 18, 740-750. - PubMed
  190. Zhang C., Min L., Liu J., Tian W., Han Y., Qu L. and Shou C. (2016). Integrated analysis identified an intestinal-like and a diffuse-like gene sets that predict gastric cancer outcome. Tumor Biol. 37, 16317-16335 - PubMed
  191. Zhang W., Gu J., Chen J., Zhang P., Ji R., Qian H., Xu W. and Zhang X. (2017). Interaction with neutrophils promotes gastric cancer cell migration and invasion by inducing epithelial-mesenchymal transition. Oncol. Rep. 38, 2959-2966. - PubMed
  192. Zhang W., Shu Y., Zhang W., Hou Q., Zhao L., Zhang S., Zhou J., Song X., Zhang Y., Jiang D., Chen X., Wang P., Xia X., Liao F., Yin D., Chen X., Zhou X., Zhang D., Yin S., Yang K., Liu J., Yang L., Fu L., Zhang L., Wang Y., Zhang J., An Y., Cheng H., Zheng B., Sun H., Zhao Y., Wang Y., Xie D., Ouyang L., Wang P., Qiu M., Fu X., Dai L., He G., Yang H., Cheng W., Liu B., Li W., Dong B., Zhou Z., Wei Y., Peng Y., Xu H. and Hu J. (2018). Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer. Nat. Commun. 9, 2447 - PubMed
  193. Zhang N., Cao M., Duan Y., Bai H., Li X. and Wang Y. (2019). Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis and experimental validation. Arch. Med. Sci. 16, 1092-1103. - PubMed
  194. Zhang N., Wang D., Duan Y., Ayarick V.A., Cao M., Wang Y., Zhang G. and Wang Y. (2020). The special immune microenvironment of tumor budding and its impact on prognosis in gastric adenocarcinoma. Pathol. Res. Pract. 216, 152926. - PubMed
  195. Zhao R., Jiang W., Li X., Zhang W., Song L., Chang Z., Cao W., Cao X. and Zong H. (2016). Anaplastic lymphoma kinase (ALK) gene alteration in gastric signet ring cell carcinoma. Cancer Biomark. 16, 569-574. - PubMed
  196. Zhao X., Cai A., Xi H., Song Y., Wang Y., Li H., Li P. and Chen L. (2017). Predictive factors for lymph node metastasis in early gastric cancer with signet ring cell histology: a meta-analysis. ANZ J. Surg. 87, 981-986. - PubMed
  197. Zhao L.Y., Wang J.J., Zhao Y.L., Chen X.Z., Yang K., Chen X.L., Zhang W.H., Liu K., Song X.H., Zheng J.B., Zhou Z.G., Yu P.W., Li Y. and Hu J.K. (2018). Superiority of tumor location-modified Lauren classification system for gastric cancer: A multi-institutional validation analysis. Ann. Surg. Oncol. 25, 3257-3263. - PubMed
  198. Zhao Z.T., Yuan H.Y., Song Y.M., Li Y., Ma F.H. and Tian Y. T. (2020). Identification of key genes and pathways in gastric signet ring cell carcinoma based on transcriptome analysis. World J. Clin. Cases 8, 658-669. - PubMed
  199. Zheng X., Song X., Shao Y., Xu B., Chen L., Zhou Q., Hu W., Zhang D., Wu C., Tao M., Zhu Y. and Jiang J. (2017). Prognostic role of tumorinfiltrating lymphocytes in gastric cancer: A meta-analysis. Oncotarget 8, 57386-57398. - PubMed
  200. Zhou M.l., Kang M., Li G.C., Guo X.M. and Zhang Z. (2016). Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: An up-todate meta-analysis. World J. Surg. Oncol. 14, 209. - PubMed
  201. Zhou L., Li W., Cai S., Yang C., Liu Y. and Lin Z. (2019). Large tumor size is a poor prognostic factor of gastric cancer with signet ring cell: Results from the surveillance, epidemiology, and end results database. Medicine (Baltimore) 98, e17367. - PubMed
  202. Zhou Q.P., Ge Y.H. and Liu C.Y. (2020). Comparison of metastasis between early-onset and late-onset gastric signet ring cell carcinoma. BMC Gastroenterol. 20, 380. - PubMed
  203. Zurlo I.V., Basso M., Strippoli A., Calegari M.A., Orlandi A., Cassano A., Di Salvatore M., Garufi G., Bria E., Tortora G., Barone C. and Pozzo C. (2020). Treatment of locally advanced gastric cancer (LAGC): Back to lauren’s classification in pan- cancer analysis era? Cancers (Basel). 12, 1-11. - PubMed

Publication Types

Grant support